Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Bridge Venture Aligns With Takeda Externalization Strategy

Executive Summary

A new collaborative academic-industry medicines development venture involving Takeda has started operations in the US, aiming to smooth and speed the passage of basic research projects through clinical trials and eventually to the market.

You may also be interested in...



Entyvio Takes Lead As Takeda Pursues Turnaround

Takeda’s CEO says the company is continuing to deliver on its turnaround plan after a stronger first half, with Entyvio providing much of the momentum for the underlying growth and a brighter full-term outlook.

Refocus, Optimize, Externalize: Takeda Overhauls Global R&D

As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.

Astellas Positions Patients At Center Of Digital Push

While Astellas, like many other large pharma firms globally, is pursuing the adoption of digital technologies across multiple disciplines, it is aiming to keep patients at the center of its initiatives and also sees a strong need for the "best mix" of the human touch and technology. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC097579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel